Results 251 to 260 of about 235,111 (295)

What Is a Balanced Way of Anticoagulation for Efficacy and Safety in High-Risk Elderly Patients With Atrial Fibrillation?

Daehoon Kim
openalex   +2 more sources

Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoadsorption – A prospective monocenter pilot study

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Bullous pemphigoid (BP) is the most common autoimmune blistering disease in the Western world. While remission is achieved in the majority of BP patients by long‐term use of corticosteroids with or without immunomodulants/immunosuppressants, national and international guidelines recommend adjuvant immunoadsorption (IA)
Maike M. Holtsche, Nina van Beek, Christoph M. Hammers, Artem Vorobyev, Michael Kasperkiewicz, Nina Schumacher, Philip Muck, Enno Schmidt   +7 more
wiley   +1 more source

Reducing Anticoagulation Duration for Children After a Provoked Deep Venous Thrombosis. [PDF]

J Am Board Fam Med
Feijóo B, Radi R, Lyon C.
europepmc   +1 more source

Pulmonary Embolism in a Patient With Undifferentiated Dyspnoea. [PDF]

Cureus
Chor YH.
europepmc   +1 more source

Machine learning‐based prediction of atrial fibrillation in patients with atrial high‐rate episodes

European Journal of Clinical Investigation, EarlyView.
Abstract Background Given the modest performance of available predictive models in estimating the risk of atrial fibrillation (AF) in patients with atrial high‐rate episodes (AHREs) detected by cardiac implantable electronic devices (CIEDs), this study explores the potential use of machine learning (ML) algorithms in this context. Purpose To assess the
Amir Askarinejad, Tommaso Bucci, Niloofar Asgharzadeh, Zahra Amirjam, Enrico Tartaglia, Michele Rossi, Yang Chen, Yalin Zheng, Gregory Y. H. Lip, Majid Haghjoo   +9 more
wiley   +1 more source

Optimal Anticoagulation for Massive Left Atrial Appendage Thrombus in Atrial Fibrillation With a History of Gastrointestinal Bleeding. [PDF]

Cureus
Hoang VTA, Dinh HTT, Lam VS, Le PNT, Tran P.   +4 more
europepmc   +1 more source

Effectiveness of direct oral anticoagulants for all‐cause mortality and cardiovascular events in overweight and obese patients with atrial fibrillation: Insight from the nationwide START registry

European Journal of Clinical Investigation, EarlyView.
This study shows that overweight and obese patients with atrial fibrillation experience improved outcomes when treated with DOACs compared with VKAs. Specifically, DOAC use was associated with lower risks of all‐cause mortality and cardiovascular events.
Danilo Menichelli, Gianluca Gazzaniga, Emilia Antonucci, Gualtiero Palareti, Daniela Poli, Pasquale Pignatelli, Daniele Pastori, the START2 Register Investigators, Benilde Cosmi, Daniela Poli, Elena Lotti, Martina Berteotti, Walter Ageno, Giovanna Colombo, Salvatore Bradamante, Eugenio Bucherini, Monica Vastola, Paola Casasco, Antonio Chistolini, Alessandra Serrao, Luciano Crippa Ambulatorio Emostasi, Raimondo De Cristofaro, Erica De Candia, Valeria De Micheli, Marcello Di Nisio, Anna Falanga, Teresa Lerede, Elvira Grandone, Donatella Colaizzo, Antonio Insana, Nicola Lucio Liberato, Domenico Lione, Rosa Maria Lombardi, Giacomo Lucarelli, Giuseppe Malcangi, Catello Mangione, Giuliana Martini Centro Emostasi, Marco Marzolo, Giovanni Nante, Vincenzo Oriana, Paolo Pedico, Simona Pedrini, Vittorio Pengo, Antonietta Piana, Francesco Cibecchini, Simona Pezzella, Pasquale Pignatelli, Daniele Pastori, Vincenza Rossi, Lucia Ruocco, Paolo Chiarugi, Serena Rupoli, Domizio Serra, Carmine Spataro, Margherita Reduzzi, Sophie Testa, Oriana Paoletti, Vincenzo Toschi, Claudio Vasselli   +58 more
wiley   +1 more source

Splenic Infarction in Babesiosis: A Case Series. [PDF]

J Brown Hosp Med
Arant K, Agaisse T, Vassilopoulos A, Ghanem S, Santos M.   +4 more
europepmc   +1 more source

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley   +1 more source